Overview

TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients

Status:
Unknown status
Trial end date:
2021-10-30
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the effectiveness of Anlotinib in middle-advanced Hepatocellular Carcinoma (HCC) Patients.
Phase:
Phase 2
Details
Lead Sponsor:
Zhejiang Cancer Hospital
Treatments:
Chlorotrianisene